Impact of 21st Century Cures Act on Breakpoints and Commercial Antimicrobial Susceptibility Test Systems: Progress and Pitfalls

The Point of Antimicrobial Susceptibility Testing Is to Inform Antimicrobial Prescribing: Table 1.

(2016) Kayla R. Stover et al.   CLINICAL INFECTIOUS DISEASES

Emerging Resistance, New Antimicrobial Agents  …  but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape

(2016) R. M. Humphries et al.   CLINICAL INFECTIOUS DISEASES

Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae

(2016) Sarah M. Bartsch et al.   JOURNAL OF CLINICAL MICROBIOLOGY

The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds

(2016) Ana Espinel-Ingroff et al.   REVISTA IBEROAMERICANA DE MICOLOGIA

Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae andPseudomonas aeruginosa:I. Cephalosporins and Aztreonam

(2013) Michael N. Dudley et al.   CLINICAL INFECTIOUS DISEASES

Rationale for the 2010 Revised Susceptibility Breakpoints for Cephalosporins, Aztreonam, and Carbapenems for Enterobacteriaceae

(2012) M. N. Dudley   Journal of the Pediatric Infectious Diseases Society

Detection of Klebsiella pneumoniae Carbapenemase (KPC) Production in Non-Klebsiella pneumoniae Enterobacteriaceae Isolates by Use of the Phoenix, Vitek 2, and Disk Diffusion Methods

(2011) C. D. Doern et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Rationale for Revised Penicillin Susceptibility Breakpoints versusStreptococcus pneumoniae:Coping with Antimicrobial Susceptibility in an Era of Resistance

(2009) Melvin P. Weinstein et al.   CLINICAL INFECTIOUS DISEASES